Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end
ORIGINAL SOURCE →via Seeking Alpha
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · conflict
- [CONFLICT] Intermodal Asia
- [CONFLICT] Securing the Untrusted Agentic Development Layer
- [CONFLICT] [World Report] Health on the ballot in Senedd Cymru election
- [CONFLICT] [Perspectives] Amita Aggarwal: understanding autoimmune rheumatic diseases
- [CONFLICT] [Perspectives] Of memory, love, death, and Proust
- [CONFLICT] [Perspectives] Myopic medical harm: a man receives free colon cancer screening in Ghana